Defining super-enhancer landscape in triple-negative breast cancer by multiomic profiling.

Huang H, Hu J, Maryam A, Huang Q, Zhang Y, Ramakrishnan S, Li J, Ma H, Ma VWS, Cheuk W, So GYK, Wang W, Cho WCS, Zhang L, Chan KM, Wang X, Chin YRNature Communications, 12:2242 (2021) PMID: 33854062

Upregulation of Akt3 confers resistance to Akt inhibitors in breast cancer.

Stottrup C, Tsang T, Chin YR. Mol Cancer Ther, 15:1964 (2016) PMID: 27297869


Inhibition of Rb phosphorylation leads to mTORC2-mediated activation of Akt.

Zhang J, Xu K, Liu P, Geng Y, Wang B, Gan W, Guo J, Wu F, Chin YR, Berrios C, Lien EC, Toker A, DeCaprio JA, Sicinski P, Wei W. Mol Cell, 62:929 (2016) PMID: 27237051

PtdIns(3,4,5)P3-dependent activation of the mTORC2 kinase complex.

Liu P, Gan W, Chin YR, Ogura K, Guo J, Zhang J, Wang B, Blenis J, Cantley LC,

Toker A, Su B, Wei W. Cancer Discov, 5:1194 (2015) PMID: 26293922 


PTEN-deficient tumors depend on Akt2 for maintenance and survival.

Chin YR, Yuan X, Balk SP, Toker A. Cancer Discov, 4:942 (2014) PMID: 24838891

  • Cover image of Cancer Discov Vol. 4, Num. 8 issue

Targeting Akt3 signaling in triple-negative breast cancer.

Chin YR, Yoshida T, Marusyk A, Beck AH, Polyak K, Toker A. Can Res, 74:964

(2014) PMID: 24335962

  • Highlighted as a “Very Good” finding by Arthur Mercurio: F1000Prime Biology


Akt-ing up on SRPK1: Oncogene or tumor suppressor?

Toker A, Chin YR. Mol Cell, 54:329 (2014) PMID: 24813709


RhoB differentially controls Akt function in tumor cells and stromal endothelial cells during breast tumorigenesis.

Kazerounian S, Gerald D, Huang M, Chin YR, Udayakumar D, Zheng N, Oí’Donnell RK, Perruzzi C, Mangiante L, Pourat J, Phung T, Bravo-Nuevo A, Shechter S, McNamara S, DuHadaway J, Kocher ON, Brown L, Toker A, Prendergast GC and Benjamin LE. Can Res, 73:50 (2013) PMID: 23135917


Acetylation-Dependent Regulation of Skp2 Function.

Inuzuka H, Gao D, Finley L, Yang W, Wan L, Fukushima H, Chin YR, Zhai B, Shaik S, Lau AW, Wang Z, Gygi SP, Nakayama K, Teruya-Feldstein J, Toker A, Haigis MC, Pandolfi PP and Wei W. Cell, 150:179 (2012) PMID: 22770219


mTOR drives its own activation via SCF(βTrCP)-dependent degradation of the mTOR inhibitor DEPTOR.

Gao D, Inuzuka H, Tan MK, Fukushima H, Locasale JW, Liu P, Wan L, Zhai B, Chin YR, Shaik S, Lyssiotis CA, Gygi SP, Toker A, Cantley LC, Asara JM, Harper JW and Wei W. Mol Cell, 44:290 (2011) PMID: 22017875


NFAT promotes carcinoma invasive migration through glypican-6.

Yiu GK, Kaunisto A, Chin YR and Toker A. Biochem J, 440:157 (2011) PMID: 21871017


Akt isoform-specific signaling in breast cancer: Uncovering an anti-migratory role for palladin.

Chin YR and Toker A. Cell Adh Migr, 5:211 (2011) PMID: 21519185


The actin bundling protein palladin is an Akt1-specific substrate that regulates breast cancer cell migration.

Chin YR and Toker A. Mol Cell, 38:333 (2010) PMID: 20471940

  • Featured in a press release on the BIDMC website

  • Featured in Breast Cancer Network News

  • Highlighted as a “Must Read” finding by Brendan Manning: Faculty of 1000 Biology


Akt2 regulates expression of the actin-bundling protein palladin.

Chin YR and Toker A. FEBS Lett, 584:4769 (2010) PMID: 21050850


Akt/Protein kinase B and glycogen synthase kinase-3β signaling pathway regulates cell migration through the NFAT1 transcription factor.

Yoeli-Lerner M, Chin YR, Hansen CK, and Toker A. Mol Cancer Res 7:425 (2009) PMID: 19258413


Phosphorylation by Akt1 promotes cytoplasmic localization of Skp2 and impairs APC-Cdh1-mediated Skp2 destruction.

Gao D, Inuzuka H, Tseng A, Chin RY, Toker A, and Wei W. Nat Cell Bio 11:397 (2009) PMID: 19270695


 Function of Akt/PKB signaling to cell motility, invasion and the tumor stroma in cancer.

Chin YR and Toker A. Cell Signal 21:470 (2009) PMID: 19110052


PDK1 potentiates upstream lesions on the PI3K pathway in breast carcinoma.

Maurer M, Su T, Koujak S, Hopkins BD, Saal LH, Barkley CR, Wu J, Nandula S, Dutta B, Xie Y, Chin YR, Kim D, Ferris JS, Gruvberger-Saal SK, LaaksoM, Wang X, Memeo L, Rojtman A, Matos T, Yu JS, Cordon-Cardo C, Isola J, Terry MB, Toker A, Landry DW, Mills GB, Zhao JJ, Murty VV, Hibshoosh H, Parsons R. Can Res 69:6299 (2009) PMID: 19602588


The Adenovirus RID complex enhances degradation of internalized tumor necrosis factor receptor 1 without affecting its rate of endocytosis.

Chin YR, and Horwitz MS. J Gen Virol, 87:3161 (2006) PMID: 15542663


 Mechanism for removal of TNF receptor 1 from the cell surface by the Adenovirus RIDα/β complex.

Chin YR, and Horwitz MS. J Virol, 79:21 (2005) PMID: 16227281


Inhibition of TNF signal transduction by the Adenovirus group C RID complex involves downregulation of surface levels of TNF receptor 1.

Fessler SP, Chin YR, and Horwitz MS. J Virol, 78:23 (2004) PMID: 15542663


 High-throughput screening of potential inhibitors for the metabolism of the investigational anti-cancer drug 5,6-dimethylxanthenone-4-acetic acid.

Zho S, Chiang D, Chin R, Kestell P, Paxton JW. J Chromatogr B Analyt Technol Biomed Life Sci. 767:19 (2002) PMID: 11863291


Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic (DMXAA) by human liver microsomes.

Zhou S, Chin R, Kestell P, Tingle MD, Paxton JW. Br J Clin Pharmacol. 52:129. (2001) PMID: 11488768